NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives
Estimated value
—
Awarded value
£160.0m
Suppliers
2
Lots
1
Published
26 Feb 2026
Description
Project title: NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives commencing 1st April 2026 Offer reference number: CM/TNS/25/5737 Period of framework: 1 April 2026 to 31 March 2028 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
Scope
- Reference
- CM/TNS/25/5737
- Commercial tool
- Standalone contract
- Contract dates
- 31 Mar 2026 to 31 Mar 2028Possible extension to 31 Mar 2030
Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
- CPV classifications
- 33600000
- Contract locations
- North East England, United KingdomNorth West England, United KingdomYorkshire and the Humber, United KingdomEast Midlands, United KingdomWest Midlands, United KingdomEast of England, United KingdomLondon, United KingdomSouth East England, United KingdomSouth West England, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Price is not the only award criterion | Price is not the only award criterion and all criteria are stated in the procurement documentation | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£160.0m
Award date
25 Feb 2026
Contract start
31 Mar 2026
Contract end
31 Mar 2028